Patent application number | Description | Published |
20080213430 | Antimicrobial Peptides - The present invention relates to polypeptides having antimicrobial activity and polynucleotides having a nucleotide sequence which encodes for the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the nucleic acid constructs as well as methods for producing and using the polypeptides. | 09-04-2008 |
20090227506 | USE OF DEFENSINS AGAINST TUBERCULOSIS - The present invention relates to a method for killing or inhibiting cells of the genus | 09-10-2009 |
20100120690 | Polypeptides Having Antimicrobial Activity and Polynucleotides Encoding Same - The present invention relates to isolated polypeptides having antimicrobial activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 05-13-2010 |
20110053836 | USE OF DEFENSINS AGAINST TUBERCULOSIS - The present invention relates to a method for killing or inhibiting cells of | 03-03-2011 |
20110160122 | Polypeptides having Antimicrobial Activity and Polynucleotides Encoding Same - The present invention relates to isolated polypeptides having antimicrobial activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods for producing and using the polypeptides. | 06-30-2011 |
Patent application number | Description | Published |
20100024048 | METHOD FOR MITE PRODUCTION - A method for culturing and producing mites, such as house dust mites, comprising culturing the mites in a suitable solid growth medium, under suitable conditions and for a suitable period of time in a suitable production room, characterized in that the mites are cultured in medium comprised within a closed bag. | 01-28-2010 |
20120076825 | PHARMACEUTICAL PRODUCT COMPRISING MITE ALLERGEN EXTRACT(S) AND A METHOD FOR THE MANUFACTURE THEREOF - The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f). | 03-29-2012 |
20130280302 | PHARMACEUTICAL PRODUCT COMPRISING MITE ALLERGEN EXTRACT(S) AND A METHOD FOR THE MANUFACTURE THEREOF - The invention relates to a pharmaceutical product comprising an allergen extract or an allergoid thereof for the treatment and/or prevention of allergy and allergic asthma caused by house dust mites, which extract comprises at least one extract of mite bodies selected from the following groups a)-b): a) An extract of Der p mite bodies, and b) An extract of Der f mite bodies, and at least one extract of mite cultures selected from the following groups c)-g): c) An extract of Der p faecal particles, d) An extract of Der f faecal particles, e) An extract of Der f whole mite culture, f) An extract of an Der p whole mite culture, and g) a combination of extracts c) to f). | 10-24-2013 |
Patent application number | Description | Published |
20100128722 | QUEUING MECHANISMS FOR LTE ACCESS AND SAE NETWORKS ENABLING END-TO-END IMS BASED PRIORITY SERVICE - A system and method for queuing emergency telecommunication service requests prevent dropped connections by sending messages to nodes requesting the emergency telecommunication service that the request has been queued. This allows for an orderly queuing process and allows congestion related issues to be overcome without preempting existing network traffic. | 05-27-2010 |
20110201307 | ACCESS CONTROL FOR M2M DEVICES - A system for restricting Machine-to-Machine devices from accessing system resources in a 3GPP compliant network without adversely affecting the access of human operated devices makes use of a new network function that instructs all devices that are internally identified as M2M devices to block access. As such, M2M and H2H devices can be assigned to the same access classes, as presently required, but need not be access barred under the same circumstances. | 08-18-2011 |
20110201365 | M2M GROUP BASED ADDRESSING USING CELL BROADCAST SERVICE - A system for providing machine-to-machine (M2M) messaging in a 3GPP environment makes use of the existing cell broadcast service, optionally with extensions, to allow for M2M enabled devices to be set in groups and sent messages in an efficient manner that can reduce traffic, and provide for less battery drain. | 08-18-2011 |
20110268026 | DEVICE FOR LOW PRIORITY HANDLING - The embodiments herein relates to a method in a transceiver ( | 11-03-2011 |
20120246325 | NETWORK NODE AND METHOD TO CONTROL ROUTING OR BYPASSING OF DEPLOYED TRAFFIC DETECTION FUNCTION NODES - A network is described herein which can control, through subscriber profile data and/or policy preconfigured control data, whether deep packet inspection for data flow/s for an Internet Protocol-Connectivity Access Network (IP-CAN) session established by an end user should take place, or not, according to a defined “User Privacy Policy”, and, in the former case, to which traffic detection function (TDF) node the data flow(s) should be directed. | 09-27-2012 |
20120290452 | METHOD AND APPARATUS FOR AUTHORIZING A TRANSACTIONAL SERVICE BY A POLICY AND CHARGING CONTROL ARCHITECTURE - The present invention faces the issue of authorizing transactional services by a Policy and Charging Control system. To this end, the present invention provides for an apparatus carrying out a method of authorizing transactional services and comprising: an authorization requester for submitting a transactional service authorization request with a user identifier and a transactional service identifier, and an authorizer for receiving the transactional service authorization request. This authorizer comprises: a PCRF server for authorizing the transactional service based on subscription and service data, an OCS for authorizing the transactional service based on credit authorization, and a decider for deciding service authorization for the transactional service based on the authorizations respectively made by the PCRF server and OCS. The authorizer of this apparatus is also arranged for submitting a transactional service authorization response to the authorization requester with a decision on service authorization for the transactional service. | 11-15-2012 |
20130003576 | Node and method for communications handling - Example embodiments disclosed herein may be directed towards a system, and corresponding method, for sending machine-to-machine (M2M) application specific parameters. These parameters may allow a network operator to guide M2M application behaviour in accordance with potentially limited recourses in the network. These parameters may also be used to provide IPv6 address information to a gateway node and/or M2M server and/or Service Capability Server (SCS). | 01-03-2013 |
20140013383 | NETWORK NODE AND METHOD TO CONTROL ROUTING OR BYPASSING OF DEPLOYED TRAFFIC DETECTION FUNCTION NODES - A network is described herein which can control, through subscriber profile data and/or policy preconfigured control data, whether deep packet inspection for data flow/s for an Internet Protocol-Connectivity Access Network (IP-CAN) session established by an end user should take place, or not, according to a defined “User Privacy Policy”, and, in the former case, to which traffic detection function (TDF) node the data flow(s) should be directed. | 01-09-2014 |
20150245196 | Method and Apparatuses for Policy and Charging Control of Machine-to-Machine Type Communications - At present, applying conventional policy and charging control in scenarios where a huge amount of users is supported, such as machine-to-machine type communication devices, represents a number of drawbacks, such as the amount of data to be stored in subscriber databases and the access rate, the signalling load, and the processing performance of nodes. The present invention provides for a method of policy control and enhanced apparatuses enabling the support of user community profiles that apply to a plurality of subscribers, the generation and enforcement of community policy and charging rules derived from the user community profiles and preferably installed upon establishment of a session for a first user. Further sessions to be established for subsequent users of the plurality of users would be enforced with said community policy and charging rules without needs for handling them on individual basis. | 08-27-2015 |
Patent application number | Description | Published |
20110003894 | DERMATOLOGICAL COMPOSITIONS COMPRISING RETINOIDS, DISPERSED BENZOYL PEROXIDE AND CARRAGEENANS - Dermatological compositions containing, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and at least one gelling agent of the family of the carrageenans, are useful for treating dermatological conditions and afflictions linked to disorders of cell differentiation and/or proliferation and/or keratinization, notably for treating acne vulgaris. | 01-06-2011 |
20120100214 | Sustained-Release Tablet and Process for Preparing the Same - A method for producing a sustained-release tablet having improved stability and content uniformity is provided. The method involves first preparing a core tablet by granulating, drying, milling, blending, and compressing a mixture of active and inactive ingredients. Four coating layers are applied to the core tablet: an inner layer, an enteric coating layer, an active layer, and an outer layer. The active ingredient may be a tetracycline, such as doxycycline. A sustained-release tablet prepared according to the method is also described. | 04-26-2012 |
20130196954 | METHOD OF TREATING ACNE - An improved method for treating acne is described. The method involves 16-week, once daily, oral administration of about 40 mg doxycycline in a pharmaceutical composition containing about 30 mg doxycycline in an immediate release portion and about 10 mg doxycycline in a delayed release portion. It was surprisingly discovered that the 16-week, once daily, oral administration of about 40 mg doxycycline has achieved same or superior efficacy than that of 100 mg doxycycline, but with a significant reduction in adverse events. | 08-01-2013 |
20140010884 | DERMATOLOGICAL COMPOSITIONS COMPRISING RETINOIDS, DISPERSED BENZOYL PEROXIDE AND CARRAGEENANS - Dermatological compositions containing, in a physiologically acceptable medium, at least one retinoid, dispersed benzoyl peroxide and at least one gelling agent of the family of the carrageenans, are useful for treating dermatological conditions and afflictions linked to disorders of cell differentiation and/or proliferation and/or keratinization, notably for treating acne vulgaris. | 01-09-2014 |
20140199469 | SUSTAINED-RELEASE TABLET AND PROCESS FOR PREPARING THE SAME - A method for producing a sustained-release tablet having improved stability and content uniformity is provided. The method involves first preparing a core tablet by granulating, drying, milling, blending, and compressing a mixture of active and inactive ingredients. Four coating layers are applied to the core tablet: an inner layer, an enteric coating layer, an active layer, and an outer layer. The active ingredient may be a tetracycline, such as doxycycline. A sustained-release tablet prepared according to the method is also described. | 07-17-2014 |
20140309198 | METHOD OF TREATING ACNE - An improved method for treating acne is described. The method involves 16-week, once daily, oral administration of about 40 mg doxycycline in a pharmaceutical composition containing about 30 mg doxycycline in an immediate release portion and about 10 mg doxycycline in a delayed release portion. It was surprisingly discovered that the 16-week, once daily, oral administration of about 40 mg doxycycline has achieved same or superior efficacy than that of 100 mg doxycycline, but with a significant reduction in adverse events. | 10-16-2014 |